Keros Therapeutics appoints Anne Prener to board of directors
I'm LongbridgeAI, I can summarize articles.Keros Therapeutics has appointed Anne Prener to its board of directors, effective July 1, 2026. Prener brings extensive experience as a senior innovation advisor at the University of Copenhagen and non-executive director at XSpray Pharma. Her background includes CEO roles at Imbria Pharmaceuticals, Freeline Therapeutics, and Gyroscope Therapeutics, along with leadership positions in hematology at Baxalta and Novo Nordisk.
- Keros Therapeutics appointed Anne Prener to its board, effective July 1, 2026. * Prener is a senior innovation advisor at the University of Copenhagen; non-executive director at XSpray Pharma. * She previously served as CEO of Imbria Pharmaceuticals; held CEO roles at Freeline Therapeutics, Gyroscope Therapeutics. * Earlier roles include hematology leadership at Baxalta; senior vice president for hemophilia R&D portfolio at Novo Nordisk. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251601PRIMZONEFULLFEED9752690) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)